Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype

Snapshot: Where RXRX Stands Going Into the New Week

Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at roughly 33 million shares, and the stock now trades near the bottom of its 52‑week range of $3.79–$12.36. ^[1]

The company’s market capitalization sits a little above $2.1 billion, and technically RXRX remains below both its 50‑day and 200‑day moving averages (around $5.2 and $5.1 respectively), underscoring how deep the recent pullback has been despite Friday’s sharp bounce. ^[2]

Because U.S. markets are closed today (Sunday, November 23), this weekend update is built around Friday’s close and fresh news published today.

Today’s Fresh News on RXRX (23 November 2025)

1. MarketBeat: Consensus Rating Locked at “Hold”

MarketBeat published a new piece today confirming that Wall Street’s current consensus on Recursion is “Hold.” Six research firms now officially cover RXRX:

1 Sell
3 Hold
2 Buy

The average 12‑month price target is $7.25, implying notable upside from Friday’s $4.17 close but still signalling caution rather than a strong conviction buy call. ^[3]

The article highlights:

Q3 2025 EPS of ‑$0.36, beating estimates by a cent or two.
Q3 revenue of $5.18 million, down 80% year‑on‑year, with a negative net margin of roughly –1,000%. ^[4]

Analysts collectively expect full‑year 2025 EPS around –$1.57, underscoring that this is still a high‑burn, early‑stage biotech rather than a cash‑generating pharma name. ^[5]

2. MarketBeat: Kingsview Wealth Management Quadruples Its RXRX Stake

A second MarketBeat alert today focuses on Kingsview Wealth Management LLC, which disclosed that it increased its position in Recursion by 502.3% during Q2. The firm added 85,598 shares to bring its total to 102,638 shares, valued at about $519,000 at the time of the filing. ^[6]

Key takeaways from that report:

Kingsview’s move is one of several institutional adjustments; multiple smaller firms have opened or increased positions.
MarketBeat estimates that about 89% of RXRX shares are now held by institutions and hedge funds. ^[7]

This doesn’t automatically make the stock a buy, but it does suggest professional money is still actively trading around the Recursion story, even as fundamentals and sentiment remain mixed.

3. DailyForex: Recursion Joins a Shortlist of Healthcare Stocks “Worth Considering”

In an article created today titled “The Best Healthcare Stocks to Buy Now – 23/11/2025”, DailyForex lists Recursion Pharmaceuticals (RXRX) on a shortlist of healthcare names the author considers currently worth considering, alongside majors like Novo Nordisk, Pfizer and Merck. ^[8]

The piece is primarily educational and focuses on how to evaluate healthcare stocks, but the inclusion of RXRX in a curated list of healthcare ideas shows that some market commentators still see speculative upside in the name, especially tied to its AI‑driven platform and partnerships.

Price Action: Friday’s Bounce After a Brutal Stretch

Technical research platform StockInvest.us upgraded Recursion from a Sell to a Hold candidate after Friday’s rally. Their commentary notes that: ^[9]

RXRX rose 8.31% on Friday, from $3.85 to $4.17.
The stock swung more than 10% intraday (low $3.85, high $4.26), underscoring very high volatility.
Despite the bounce, RXRX is down about 9–10% over the last 10 trading days.
Daily volatility around 9–10% and a wide horizontal trading range lead their system to label the stock “very high risk” in the near term.

From a short‑term technical standpoint, RXRX is:

Near support around ~$4.10–$4.15.
Facing resistance in the mid‑$4s and above, with stronger resistance around ~$4.60–$5.30. ^[10]

In other words: Friday’s rebound may have relieved some pressure, but the chart still reflects a down‑trending, high‑beta AI biotech with considerable headline sensitivity.

Under the Hood: What Recursion Actually Does

Despite the meme‑stock chatter around RXRX, Recursion is not a pure hype vehicle. It’s a clinical‑stage “TechBio” company trying to industrialize drug discovery using a mix of:

High‑throughput biology and chemistry
Robotics and lab automation
Massive proprietary datasets
Machine‑learning and generative AI

Its pipeline includes multiple internal programs, such as: ^[11]

REC‑994 – Phase 2 for cerebral cavernous malformation
REC‑2282 – Phase 2/3 for neurofibromatosis type 2
REC‑4881 – Phase 1b/2 for familial adenomatous polyposis and AXIN1/APC‑mutant cancers
REC‑3964 – Phase 1 for C. difficile infection
Newer oncology candidates such as REC‑1245 (RBM39 degrader) and REC‑617 (CDK7 inhibitor) in early‑stage trials

None of these programs are yet in late‑stage (Phase 3) development, which is one big reason analysts remain cautious.

AI Supercomputers and Boltz‑2

Recursion has invested heavily in AI infrastructure:

Its BioHive‑2 GPU supercomputer, built with NVIDIA, ranks among the most powerful systems in the pharmaceutical industry. ^[12]
In partnership with MIT, Recursion helped develop Boltz‑2, an open‑source AI model that predicts both protein structure and binding affinity. NVIDIA highlights that Boltz‑2 can approach the chemical accuracy of expensive physics‑based simulations while running about 1,000x faster, screening huge libraries in hours instead of weeks. ^[13]

NVIDIA’s CEO Jensen Huang has publicly praised Recursion’s work in “digital biology and chemistry” and called out their collaboration to build some of the largest biomolecular generative AI models for drug discovery. ^[14]

This high‑end AI stack is central to the bullish argument: if Recursion can turn this data and compute advantage into real, de‑risked drug assets, the current valuation could one day look cheap. If it can’t, the cash burn becomes a problem very fast.

Pharma Partnerships and the Exscientia Merger

Recursion’s business model blends in‑house drug development with big‑pharma collaborations. Over the past few years, it has signed deals with companies like Sanofi, Roche/Genentech, Bayer, Takeda and Merck KGaA, often focused on oncology and fibrotic diseases. ^[15]

In 2024–2025 it also completed a major all‑stock merger with UK AI‑biotech Exscientia, giving Recursion more AI talent, an expanded pipeline and a stronger European presence:

Exscientia shareholders received about 0.77 RXRX shares for each EXAI ADS, with the deal value frequently quoted around $700–850 million, depending on share prices at various points. ^[16]
A recent CoinCentral analysis notes that on a trailing 12‑month basis Recursion generated $64.5 million of revenue, spent around $431 million on R&D and posted a net loss of roughly $649 million, as it absorbed Exscientia and continued to scale its platform. ^[17]

Those numbers explain both sides of the investment debate: enormous investment and potential, paired with very heavy ongoing losses.

Financial Reality: Deep Losses but a Long Runway

Q3 2025 Results

For Q3 2025, Recursion reported: ^[18]

Revenue: ~$5.18 million (vs. ~$26.1 million a year earlier, –80% YoY)
Net loss: about $162 million (vs. ~$96 million a year ago)
EPS: –$0.36 (slightly better than consensus of –$0.37 to –$0.38)
R&D spend: roughly $120+ million in the quarter

The revenue decline reflects the lumpy nature of collaboration and milestone payments — last year’s Q3 benefited from larger partner revenue, while this year’s quarter did not. But regardless of timing issues, the company is clearly burning far more cash than it is generating.

Balance Sheet and Cash Runway

As of September 30, 2025, Recursion reported about $667 million in cash, cash equivalents and marketable securities.
Management has also drawn on an at‑the‑market (ATM) equity program, and several analyst notes now suggest the company has runway into 2027 if it executes on updated cash‑burn guidance. ^[19]

That gives Recursion time — but not infinite time — to deliver meaningful pipeline progress and partnership milestones before markets begin to worry more seriously about another big equity raise.

Leadership Transition: Najat Khan to Take the Helm

On November 5, Recursion announced a CEO transition: ^[20]

Co‑founder Chris Gibson will move from CEO to Executive Chair of the Board.
Dr. Najat Khan, currently Chief Commercial and R&D Officer (and formerly a senior leader at Johnson & Johnson), is slated to become CEO in early 2026.

A STAT News profile of Khan frames this as a pivotal moment: Recursion has trimmed parts of its pipeline, integrated Exscientia, and now needs to prove its AI platform with concrete clinical wins and value‑creating deals. ^[21]

TipRanks notes that TD Cowen analyst Brendan Smith reiterated a Hold rating on November 1, citing: ^[22]

Solid platform progress and reaffirmed guidance for 2025–2026
An extended cash runway supported in part by the ATM program
But also uncertainty around the upcoming leadership transition and the fact that key pipeline assets like REC‑617 are still in early‑stage trials

In short, Wall Street likes the direction of the platform but wants to see execution under new leadership before upgrading the stock.

Ownership, Short Interest and Flow of Funds

Institutional and Hedge Fund Activity

Between MarketBeat, Fintel and other holdings trackers, the picture that emerges is: ^[23]

A large majority of RXRX shares are held by institutions.
Firms like BlackRock, Vanguard and Bank Pictet & Cie have taken substantial positions over the last year.
Smaller managers such as Kingsview and SBI Securities have also added shares in recent quarters.
At the same time, some investors – including ARK Invest – have periodically trimmed their holdings, even as ARK recently bought about $2.09 million worth of RXRX as part of a wider tech and biotech reshuffle on November 18.

This pattern reinforces the idea that RXRX has become a battleground AI‑biotech: plenty of institutional believers, but also plenty of skeptics.

Short Interest and Insider Selling

Recent analyses of Recursion’s valuation highlight very high short interest, with estimates earlier in the year around 30%+ of free float and well over 100 million shares sold short. TechStock²

On top of that, CoinCentral points out that over the last six months: ^[24]

Insiders executed nine sales and zero purchases.
CEO Chris Gibson alone sold more than 1.1 million shares, raising roughly $5.87 million.
Other senior leaders, including incoming CEO Najat Khan, also sold smaller blocks.

Insider sales don’t automatically mean trouble — they can be tied to pre‑scheduled plans or diversification — but combined with high short interest and ongoing dilution from equity raises, they contribute to the cautious stance many analysts are taking.

How the Market Is Framing RXRX Right Now

Putting all the recent data points together, RXRX is being framed as:

Bullish Talking Points

Category‑defining AI platform with world‑class compute (BioHive‑2) and models (Boltz‑2), plus deep partnerships with Sanofi, Roche, Bayer and others. ^[25]
A significantly broadened pipeline and AI toolkit thanks to the Exscientia merger. ^[26]
A large cash pile, with management and coverage suggesting a runway into 2027 if costs remain under control. ^[27]
High institutional ownership and fresh buying from firms like Kingsview Wealth Management and ARK Invest, suggesting continued professional interest. ^[28]

Bearish Talking Points

No late‑stage (Phase 3) programs yet and no approved products; the story is still largely about future potential. ^[29]
Heavy and rising losses: roughly $649 million in net losses over the last 12 months, with R&D spend many times higher than revenue. ^[30]
High short interest and a history of dilution via new share issuance. ^[31]
Insider selling with no offsetting insider buys in recent months. ^[32]
A consensus rating of Hold, not Buy, with average price targets clustered in the mid‑single digits (roughly $6–7), implying modest upside from current levels. ^[33]

What Today’s News Means for RXRX Investors

From a November 23, 2025 perspective, today’s batch of headlines doesn’t radically change the Recursion story, but it does sharpen the picture:

Analyst consensus is firming up around “Hold.”
MarketBeat, TipRanks and others all point to a mixed Wall Street view: analysts acknowledge the platform and pipeline progress but are waiting for clearer, later‑stage clinical proof and post‑merger execution before turning broadly bullish. ^[34]
Institutional money is still engaged.
Kingsview’s 500%+ position increase and recent ARK purchases show that professional investors are still willing to allocate capital to RXRX at these levels, even as others trim. This kind of push‑and‑pull flow often underpins volatile, range‑bound trading. ^[35]
Retail‑facing media are split between excitement and caution.
DailyForex putting Recursion on a shortlist of healthcare stocks “worth considering” contrasts with other commentaries that emphasize the large losses, insider selling and the possibility that other AI names offer cleaner risk‑reward profiles. ^[36]
The near‑term trading setup is high‑risk, high‑volatility.
Friday’s 8% move, double‑digit intraday swings and StockInvest’s “hold candidate / very high risk” assessment all point to a stock where small news items can trigger large price reactions, especially given the elevated short interest. ^[37]

For investors, that translates into a fairly clear message:

RXRX today is not a steady defensive healthcare stock; it’s a speculative AI‑biotech bet whose value will ultimately depend on clinical outcomes, deal flow and how effectively new leadership can turn a powerful AI platform into de‑risked assets.
The latest November 23 headlines reinforce, rather than overturn, the market’s current stance: interesting long‑term upside, but with substantial execution, financing and volatility risk.

Nothing in this article is financial advice or a personalized recommendation. If you’re considering Recursion Pharmaceuticals stock, it’s important to evaluate your own risk tolerance, time horizon and diversification, and to consider speaking with a qualified financial professional before making any investment decisions.